RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024 ...Middle East

YANTAI, China, March 10, 2024 /PRNewswire/ -- RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an interim analysis of the evaluation of the Company's proprietary Disitamab Vedotin (RC48), an...

Hence then, the article about remegen presents oral presentation on evaluation of its proprietary disitamab vedotin rc48 for cervical cancer at esgo 2024 was published today ( Monday 11/03/2024 - 05:29 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024 )

Also on site :

• Johnny Knoxville Takes Credit For “Monstrous Explosion” In Simi Valley During ‘Jackass: Best and Last’ Wrap
• Indigo Girls’ Emily Saliers Reveals Cervical Dystonia and Essential Tremor Diagnoses: ‘My Voice Will Not Be What It Was’
• SK hynix Begins Mass Production of 192GB SOCAMM2 'Setting a New Standard for AI Server Memory Performance'